Wolfe Research analyst Kalpit Patel upgraded Corcept Therapeutics (NASDAQ: CORT) from Underperform to Peerperform.

The analyst commented, "Corcept received FDA approval for relacorilant in 2L+ PROC. While we continue to question the sustainability of the core Cushing's franchise, we see the ovarian approval as removal of a key downside scenario for the stock; upgrade to Peer Perform"

For an analyst ratings summary and ratings history on Corcept Therapeutics click here. For more ratings news on Corcept Therapeutics click here.

Shares of Corcept Therapeutics closed at $33.82 yesterday.